🇺🇸 FDA
Patent

US 8658671

Crystalline form of a quinolinone-carboxamide compound

granted A61KA61K31/46A61P

Quick answer

US patent 8658671 (Crystalline form of a quinolinone-carboxamide compound) held by Theravance, Inc. expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Feb 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/46, A61P, A61P1/00, A61P1/04